Standard of Care FVIII Replacement therapy ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 288 | Autoimmune acquired coagulation factor deficiency | 1 |
288. Autoimmune acquired coagulation factor deficiency
Clinical trials : 206 / Drugs : 231 - (DrugBank : 28) / Drug target genes : 10 - Drug target pathways : 21
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03876301 (ClinicalTrials.gov) | January 21, 2019 | 11/3/2019 | Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants | A Multi-Center, Observational Study in Males With Hemophilia A | Blood Coagulation Disorder;Blood Coagulation Disorders, Inherited;Coagulation Protein Disorders;Hemophilia A;Genetic Diseases, Inborn;Genetic Diseases, X-Linked;Hematologic Diseases;Hemorrhagic Disorders;Factor VIII Deficiency | Drug: Standard of Care FVIII Replacement therapy | Spark Therapeutics | NULL | Active, not recruiting | 18 Years | N/A | Male | 55 | United States;Australia;Canada;Thailand |